Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

Exclusion Criteria

• •History of previous infection with hookworm.
• •Prior extensive and continuous travel, work, or residence (\> 1 month) in a hookworm-endemic region.
• •Pregnancy as determined by a positive urine hCG test (if female).
• •Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history or physical examination.
• •Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer to understand and cooperate with the study protocol.
• •Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
• •Participation in an investigational vaccine or drug trial within 14 days of starting this study.
• •Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
• •History of a severe allergic reaction or anaphylaxis.
• •Known immunodeficiency syndrome.
• •Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.
• •History of a surgical splenectomy.
• •Extensive dermatitis precluding skin testing
• •Current use of a beta blocker (oral or topical) or anti-histamine medication. A volunteer may participate in the study if they agree to withhold use of an anti-histamine for at least 5 days prior to application of the skin test.
• •Use of a tricyclic anti-depressant within the past month.